Inhibition of moloney sarcoma virus (MSV) induced cytopathicity in C3H/3T3 embryo fibroblast cells
|
Moloney murine sarcoma virus
|
0.25
ug.mL-1
|
|
Compound was tested for antiviral activity against the CEM-SS cell lines infected with HIV-1.
|
Homo sapiens
|
420.0
nM
|
|
Inhibition of Human immunodeficiency virus (HIV) -1 III B strain induced cytopathicity in CEM cell line
|
None
|
1.8
ug.mL-1
|
|
Inhibition of Human immunodeficiency virus (HIV)-2 ROD strain induced cytopathicity in CEM cell line
|
None
|
2.5
ug.mL-1
|
|
Cellular toxic effect was determined in CEM cells
|
Homo sapiens
|
285.0
ug.mL-1
|
|
Inhibitory activity against herpes simplex virus type 1 (HSV-1) KOS strain
|
Human herpesvirus 1
|
3.6
ug.mL-1
|
|
Inhibition of herpes simplex virus type 1 thymidine kinase (HSV-1 TK-) B2006 strain
|
None
|
13.0
ug.mL-1
|
|
Inhibitory activity against herpes simplex virus type 1 (HSV-1) thymidine kinase (TK) VMW 1837 strain
|
None
|
5.0
ug.mL-1
|
|
Inhibitory activity against herpes simplex virus type 2 (HSV-2) G strain
|
Human herpesvirus 2
|
1.1
ug.mL-1
|
|
Inhibitory activity against vaccinia virus (VV)
|
Vaccinia virus
|
1.14
ug.mL-1
|
|
Inhibition of Herpes simplex virus-1, KOS strain induced cytopathicity in E6SM cell line
|
None
|
7.0
ug.mL-1
|
|
Inhibition of Herpes simplex virus-2 (G strain) induced cytopathicity in E6SM cell line
|
None
|
7.0
ug.mL-1
|
|
Inhibition of thymidine kinase deficient Herpes simplex virus-1 VMW 1837 strain induced cytopathicity in E6SM cell line
|
None
|
7.0
ug.mL-1
|
|
Concentration required to inhibit 50% of cytoplasmic HBV-DNA synthesis
|
Human herpesvirus 1
|
200.0
nM
|
|
Inhibition of Thymidine kinase deficient (TK-) Varicella-Zoster virus (VZV) 07/1 strain induced cytopathicity n HEL cell line
|
Human herpesvirus 3
|
10.0
ug.mL-1
|
|
Inhibition of Thymidine kinase deficient (TK-) Varicella-Zoster virus (VZV) YS/R strain induced cytopathicity in HEL cell line
|
None
|
10.0
ug.mL-1
|
|
Inhibition of Varicella-Zoster virus (VZV) OKA strain induced cytopathicity in HEL cell line
|
None
|
10.0
ug.mL-1
|
|
Inhibition of Varicella-Zoster virus (VZV) YS strain induced cytopathicity in HEL cell line
|
None
|
10.0
ug.mL-1
|
|
Inhibition of cytopathogenicity against human HIV-1(IIIB) in MT-4 cells
|
Human immunodeficiency virus 1
|
4.1
ug.mL-1
|
|
Inhibition of cytopathogenicity against human HIV-2(LAV-2) in MT-4 cells
|
Human immunodeficiency virus 2
|
3.8
ug.mL-1
|
|
Inhibitory activity against cytomegalovirus (CMV) AD 169 strain
|
Cytomegalovirus
|
30.0
ug.mL-1
|
|
Inhibitory activity against cytomegalovirus (CMV) Davis strain
|
Cytomegalovirus
|
77.0
ug.mL-1
|
|
Inhibitory activity against varicella zoster virus thymidine kinase (VZV TK+) OKA strain
|
Human herpesvirus 3
|
8.5
ug.mL-1
|
|
Inhibitory activity against varicella zoster virus thymidine kinase (VZV TK+) YS strain
|
Human herpesvirus 3
|
5.4
ug.mL-1
|
|
Inhibition of varicella zoster virus thymidine kinase (VZV TK+) YS/R strain
|
Human herpesvirus 3
|
18.0
ug.mL-1
|
|
Cellular toxic effect was determined in MT-4 cells
|
Homo sapiens
|
274.0
ug.mL-1
|
|
Inhibition of antiviral activity against moloney murine sarcoma virus(MSV)in CEM cells in cell protection assay
|
Moloney murine sarcoma virus
|
2.0
ug.mL-1
|
|
Inhibition of murine sarcoma virus-induced transformation of mouse embryo fibroblast C3H/3T3 cells after 6 days
|
Moloney murine leukemia virus
|
530.0
nM
|
|
Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
5.8
ug.mL-1
|
|
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
18.0
ug.mL-1
|
|
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
9.1
ug.mL-1
|
|
Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
128.0
ug.mL-1
|
|
Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
137.0
ug.mL-1
|
|
Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
90.0
ug.mL-1
|
|
Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
20.0
ug.mL-1
|
|
Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
Human herpesvirus 5
|
42.0
ug.mL-1
|
|
Antiviral activity against Hepatitis B virus
|
Hepatitis B virus
|
200.0
nM
|
|
Antiviral activity against Herpes simplex virus 1
|
Human herpesvirus 1
|
0.024
nM
|
|
Antiviral activity against Herpes simplex virus 2
|
Human herpesvirus 2
|
0.024
nM
|
|
Antiviral activity against HIV1
|
Human immunodeficiency virus 1
|
0.0033
nM
|
|
Antiviral activity against HIV2
|
Human immunodeficiency virus 2
|
0.0066
nM
|
|
Antiviral activity against Human cytomegalovirus
|
Human herpesvirus 5
|
0.1
nM
|
|
Antiviral activity against Varicella zoster virus
|
Human herpesvirus 3
|
0.035
nM
|
|
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBV DNA replication after 9 days by PCR
|
Hepatitis B virus
|
517.0
nM
|
|
Antiviral activity against HIV1 clade D isolate 1649 infected in human H9 cells assessed as inhibition of viral replication
|
Human immunodeficiency virus 1
|
320.0
nM
|
|
Antiviral activity against HIV1 clade A/E isolate 2165 infected in human H9 cells assessed as inhibition of viral replication
|
Human immunodeficiency virus 1
|
320.0
nM
|
|
Antiviral activity against HIV1 clade F isolate 2338 infected in human H9 cells assessed as inhibition of viral replication
|
Human immunodeficiency virus 1
|
190.0
nM
|
|
Antiviral activity against HIV1 clade G isolate 3187 infected in human H9 cells assessed as inhibition of viral replication
|
Human immunodeficiency virus 1
|
220.0
nM
|
|
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication after 9 days by fluorescence PCR method
|
Hepatitis B virus
|
517.0
nM
|
|
Inhibition of hepatitis B virus capsid assembly infected in human HepG2.215 cells assessed as reduction in viral DNA replication measured on day 7 by real time PCR analysis
|
Hepatitis B virus
|
82.7
nM
|
|
Antiviral activity against HBV
|
Hepatitis B virus
|
700.0
nM
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
27.72
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
41.81
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
14.69
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.05
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.0
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.05
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.0
%
|
|